From the Sector

The diabetic community has always been a priority for Hologenix, creators of CELLIANT® infrared technology, so the company embarked on an initial study to test the hypothesis that the technology can positively impact diabetic patients with vascular impairment, now published in Journal of Textile Science & Engineering. Another study is underway as well with more research on the horizon.

According to statistics cited in the International Diabetes Federation Diabetes Atlas, 9th edition, globally, close to a half billion people are living with diabetes and that number is expected to increase by more than 50 percent in the next 25 years.
 
The introduction of the study in the Journal of Textile Science & Engineering also reports that diabetic patients frequently suffer from a combination of peripheral neuropathy and peripheral artery disease, which particularly affects their feet. It further states that it has been estimated that the lifetime risk for the development of foot ulcers in diabetic patients can be as high as 25 percent and that the risk of amputation is 10 to 20 times higher than in non-diabetic subjects.
 
The study was performed by Lawrence A. Lavery, D.P.M., M.P.H., a Professor in the Department of Plastic Surgery at UT Southwestern Medical Center. His clinic and research interests involve diabetic foot complications, infections and wound healing, and he participated in the conception, design, implementation and authorship of the Journal of Textile Science & Engineering study.  

CELLIANT technology is a patented process for adding micron-sized thermo-responsive mineral particles to fibers, in this case polyethylene terephthalate (PET) fibers. The resulting CELLIANT yarns were woven into stockings and gloves containing either 82% CELLIANT polyester, 13% nylon and 5% spandex or for the placebo, 82% polyester with no CELLIANT, 13% nylon and 5% spandex. CELLIANT products absorb body heat and re-emit the energy back to the body as infrared energy, which is non-invasive and increases temporary blood flow and cell oxygenation levels in the body.

The objective of the study was to “evaluate changes in transcutaneous oxygen (TcPO2) and peripheral blood flow (laser Doppler, LD) in the hands and feet of diabetic patients with vascular impairment when CELLIANT gloves and stockings are worn.” While there was not a statistically significant result across all subjects, the study did show that some patients wearing CELLIANT stockings for 60 minutes had an increase of as much as 20% in tissue oxygenation and 30% in localized blood flow. According to the study’s conclusion, “the trends that were observed in favor of CELLIANT stockings suggest that a larger well-designed clinical trial should be undertaken and may provide evidence of clinical efficacy in treatment of the diabetic foot.”
 
The study also notes that “There have been no documented or observed side effects of wearing CELLIANT stockings, and they are relatively inexpensive compared to conventional pharmaceutical interventions.”

Hologenix has embarked on a more comprehensive trial, “Study to Evaluate CELLIANT Diabetic Medical Socks to Increase Tissue Oxygenation and Incidence of Complete Wound Closure in Diabetic Foot Wounds” – NCT04709419, which focuses on the impact of CELLIANT technology to potentially improve tissue oxygenation and wound healing outcomes.
 
“We are excited to explore whether future studies of infrared, with its most common biological effects of increased localized blood flow and cellular oxygenation, could result in a breakthrough in diabetic patients with vascular impairment,” said Seth Casden, Hologenix Co-founder and CEO. “We see a huge potential opportunity with this research for helping to fulfill our core mission of improving people’s health and well-being by potentially reducing the impact of diabetes, and we are actively seeking partners to expand our research efforts.”

• Asahi Kasei Corporation markets premium stretch fiber under the brand of ROICA™, with superior performance features enabled by integrated production from raw material to yarn based on its advanced technology.
• The specialized global holding operates its global ROICA™ business having production sites in Japan, Thailand, Taiwan, China, and Germany with strategic sales facilities around the world.

With deep regret, Asahi Kasei has taken the decision to restructure its production strategy in order to face the new, unexpected and critical market situation. As part of this process, the production and sales of ROICA™ at its German subsidiary, Asahi Kasei Spandex Europe GmbH in Dormagen, will be discontinued by March 31, 2022.
 
Recognizing the paramount importance of the European market, especially when it comes to smart innovation where ROICA™ is a leader, and with the goal of continuing the excellent longtime work with valued partners, customers and supply chains, Asahi Kasei will continue to develop sales, technical and marketing services in Europe through Asahi Kasei Europe, the European regional headquarters of the Asahi Kasei Group. It will especially focus on ROICA™ added value products manufactured at its ROICA™ production sites in Asia.
 
Through this process, Asahi Kasei will reshape the efficiency and productivity of its global ROICA™ operation by keeping a strong focus on responsible innovation and sustainability in close communication, and safeguarding its business partners.
 
As a manufacturer of superior quality, highly functional and sustainable ROICA™ products, Asahi Kasei will continue its journey of responsible innovation aiming to provide solutions to the textile industry and to contemporary consumers, by enhancing production capabilities and expertise at the global sites supported by an expert, wise and efficient company.

On the occasion of the VDMA press conference, André Wissenberg, Head of Marketing, Corporate Communications and Public Affairs at Oerlikon Polymer Processing Solutions Division, presented the company's concept for ITMA Asia with the claim: Clean Technology. Smart Factory.

Due to the Corona pandemic, Oerlikon has decided to concentrate with their Chinese sales and service teams on guests primarily from China and greater Asia. However, some experts from Germany, who are working in China at our locations anyway, will be live on site at the booth. Other experts from Germany, India and US will be available online for the entire 5 days of the trade fair and will simply be connected by video conference to the discussion with the visitors on site if there is a need for.

At ITMA Asia 2021, Oerlikon will present the next generation of an automatic texturing solution with up to 25 % energy saving and up to 30 % higher production speed, easy maintenance and best yarn quality. The core of this machine, the socalled EvoCooler, will be shown as an exhibit in combination with digital solutions like AIM4DTY. In the field of high-precision flow control solutions components, the two new gear metering pumps developments for the production of aramid and spandex will be presented as well.